ARS Pharmaceuticals, Inc. (SPRY) Insider Trading Activity

NASDAQ$4.76
Market Cap
$472.68M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
785 of 852
Rank in Industry
452 of 491

SPRY Insider Trading Activity

SPRY Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$1,949,747
4
100

Related Transactions

Fitzpatrick Alexander AChief Legal Officer
0
$0
1
$33,550
$-33,550
Dorsey BrianChief Operating Officer
0
$0
1
$190,050
$-190,050
Karas EricChief Commercial Officer
0
$0
1
$250,000
$-250,000
Chakma JustinChief Business Officer
0
$0
1
$1.48M
$-1.48M

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Insider Activity of ARS Pharmaceuticals, Inc.

Over the last 12 months, insiders at ARS Pharmaceuticals, Inc. have bought $0 and sold $1.95M worth of ARS Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at ARS Pharmaceuticals, Inc. have bought $25.62M and sold $28.64M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 505,954 shares for transaction amount of $4.95M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.

List of Insider Buy and Sell Transactions, ARS Pharmaceuticals, Inc.

2026-06-12SaleFitzpatrick Alexander AChief Legal Officer
3,355
0.0035%
$10.00
$33,550
-37.96%
2026-06-12SaleKaras EricChief Commercial Officer
25,000
0.0263%
$10.00
$250,000
-37.96%
2025-11-13SaleDorsey BrianChief Operating Officer
21,828
0.023%
$8.71
$190,050
+1.66%
2025-11-12SaleChakma JustinChief Business Officer
166,380
0.1707%
$8.87
$1.48M
-4.58%
2025-08-21SaleLowenthal Richard EPRESIDENT AND CEO
50,000
0.0499%
$14.49
$724,345
-39.07%
2025-08-21SaleScott Kathleen D.Chief Financial Officer
12,500
0.0129%
$15.00
$187,500
-39.07%
2025-08-20SaleTanimoto SarinaCHIEF MEDICAL OFFICER
37,656
0.0372%
$14.09
$530,626
-37.88%
2025-08-19SaleTanimoto SarinaCHIEF MEDICAL OFFICER
12,344
0.0129%
$14.03
$173,130
-34.23%
2025-07-01SaleKaras EricChief Commercial Officer
15,000
0.0161%
$16.99
$254,861
-39.59%
2025-06-27SaleFlynn James E10 percent owner
370,074
0.3822%
$18.46
$6.83M
-46.29%
2025-06-18SaleKaras EricChief Commercial Officer
15,000
0.0154%
$16.00
$240,000
-38.47%
2025-05-20SaleFitzpatrick Alexander AChief Legal Officer
102,969
0.1031%
$14.10
$1.45M
-29.80%
2025-05-20SaleScott Kathleen D.Chief Financial Officer
50,000
0.0501%
$14.10
$705,165
-29.80%
2025-05-20SaleSAUNDERS BRENT Ldirector
120,000
0.1215%
$14.25
$1.71M
-29.80%
2025-04-07SaleShawver Lauradirector
50,002
0.0489%
$12.30
$615,075
-15.90%
2025-03-20SaleKaras EricChief Commercial Officer
10,000
0.0101%
$14.00
$140,000
-21.59%
2025-03-06SaleShawver Lauradirector
49,600
0.0524%
$11.21
$556,046
+6.49%
2025-03-05SaleShawver Lauradirector
400
0.0004%
$11.00
$4,400
+5.70%
2025-02-03SaleShawver Lauradirector
50,000
0.0486%
$12.31
$615,565
-4.39%
2025-01-06SaleShawver Lauradirector
50,000
0.0511%
$11.10
$555,065
+10.60%
Total: 137
*Gray background shows transactions not older than one year

Insider Historical Profitability

75.72%
Fitzpatrick Alexander AChief Legal Officer
90910
0.0915%
$432,731.6022
+133.38%
Karas EricChief Commercial Officer
12176
0.0123%
$57,957.7608
Dorsey BrianChief Operating Officer
10789
0.0109%
$51,355.6405
Chakma JustinChief Business Officer
0
0%
$0012
RA CAPITAL MANAGEMENT, L.P.
9958073
10.0279%
$47.4M50
+46.88%
Flynn James E10 percent owner
4887254
4.9215%
$23.26M03
Tanimoto SarinaCHIEF MEDICAL OFFICER
1247447
1.2562%
$5.94M032
Lowenthal Richard EPRESIDENT AND CEO
1196494
1.2049%
$5.7M031
Shawver Lauradirector
210346
0.2118%
$1M022
Scott Kathleen D.Chief Financial Officer
10042
0.0101%
$47,799.9204
ORBIMED ADVISORS LLCdirector
0
0%
$014
SAUNDERS BRENT Ldirector
0
0%
$001
Thompson Peter A.director
0
0%
$014
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,481,409
33
201.68%
$474.1M
$31,271,604
28
28.69%
$481.36M
$112,238,340
19
39.16%
$467.51M
$1,057,969
14
68.06%
$418.67M
$133,809,976
13
31.29%
$545.2M
$130,748,265
10
53.98%
$560.31M
$13,258,734
9
18.72%
$418.78M
$5,529,561
8
5.30%
$502.06M
$13,043,783
8
732.82%
$445.14M
$62,616,785
8
-7.00%
$548.15M
$17,675,244
7
92.20%
$464.2M
ARS Pharmaceuticals, Inc.
(SPRY)
$21,792,890
6
75.72%
$472.68M
$4,745,999
5
-4.91%
$494.94M
$164,999,952
5
-44.44%
$499.66M
$209,740
4
-1.93%
$424.94M
$208,592
4
11.22%
$498.7M
$1,746,565
4
-29.05%
$440.94M
$20,020,000
1
-75.24%
$441.37M
$3,850,000
1
-51.32%
$440.98M

SPRY Institutional Investors: Active Positions

Increased Positions94+42.15%16M+19.6%
Decreased Positions92-41.26%11M-13.11%
New Positions36New10MNew
Sold Out Positions36Sold Out4MSold Out
Total Postitions225+0.9%89M+6.49%

SPRY Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$124,793.0010.97%10.86M00%2025-09-30
Orbimed Advisors Llc$95,235.008.37%8.29M00%2025-09-30
Deerfield Management Company, L.P.$86,219.007.58%7.5M-2M-22.84%2025-09-30
Blackrock, Inc.$55,512.004.88%4.83M+407,863+9.22%2025-09-30
Rubric Capital Management Lp$51,705.004.55%4.5M+3M+247.52%2025-09-30
Sr One Capital Management, Lp$46,108.004.05%4.01M00%2025-09-30
Vanguard Group Inc$40,218.003.54%3.5M+237,630+7.28%2025-09-30
Aberdeen Group Plc$35,585.003.13%3.1M+2M+106.11%2025-09-30
State Street Corp$33,266.002.93%2.9M+700,763+31.93%2025-09-30
Alliancebernstein L.P.$30,358.002.67%2.64M-1M-30.94%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.